Tree-in-Bud Pattern with Ground Glass Opacity: Diagnostic Approach

Primary Differential Diagnoses

The American Thoracic Society suggests that profuse poorly defined centrilobular nodules of ground-glass opacity affecting all lung zones is highly suggestive of Hypersensitivity Pneumonitis (HP) in nonsmokers 1, 2
The European Respiratory Society recommends that the three-density pattern (hypoattenuating, normal, and hyperattenuating lobules in close proximity) is highly specific for fibrotic HP, although this fact is from a less preferred source, a more relevant fact is: Inspiratory mosaic attenuation with air-trapping associated with centrilobular nodules supports this diagnosis 1, 2
The American College of Chest Physicians states that key diagnostic step for HP is to obtain detailed exposure history to organic antigens and perform BAL with lymphocyte differential 1, 2
In Asia and TB-endemic regions, the World Health Organization recommends that tuberculosis must be excluded first given high prevalence 3
The Infectious Diseases Society of America suggests that atypical infections can present with this pattern, and immediate action should include obtaining sputum cultures, acid-fast bacilli smears, and nucleic acid amplification testing for TB 3

The American College of Radiology recommends high-resolution CT with inspiratory and expiratory views to assess for mosaic attenuation and air-trapping 1, 2
The American Thoracic Society suggests that BAL lymphocyte differential >20% supports HP diagnosis 1, 2
The European Respiratory Society recommends that transbronchial biopsy increases diagnostic yield when combined with BAL, particularly in fibrotic HP 2

The American College of Chest Physicians states that immediate and complete antigen avoidance is the cornerstone of treatment for Hypersensitivity Pneumonitis 1, 2
The Infectious Diseases Society of America recommends that empiric antibiotics should be initiated immediately for bacterial pneumonia without waiting for culture results 4
The National Comprehensive Cancer Network suggests that discontinuing the offending agent immediately is crucial for drug-related pneumonitis 5

The American Thoracic Society warns not to assume infectious etiology without considering HP, especially in nonsmokers with exposure history 1, 2
The World Health Organization advises not to delay TB evaluation in endemic regions or high-risk patients 3
The American College of Chest Physicians cautions not to overlook recent medication changes, as drug-related pneumonitis can occur 3-12 weeks after drug initiation 5
The European Respiratory Society notes that extensive ground-glass opacity (>30% of lung involvement) argues against idiopathic pulmonary fibrosis and should prompt consideration of alternative diagnoses 6, 7